Vita 34 AG Sustains Growth in H1 2024, Strongly Boosts Operating Cash Flow

Leipzig-based Vita 34 AG, Europe's leading cell bank, has reported continued positive business performance in the first half of 2024. The company's revenues grew by 4.9% to EUR 38.0 million compared to the previous year. EBITDA surged by 76.4% to EUR 2.7 million, enhancing the EBITDA margin to 7.2%, up from 4.3%.

Operating cash flow saw significant improvement, increasing by 48.8% to EUR 4.3 million. Key drivers included robust demand for contract renewals and effective price adjustments countering inflation. Despite a slight dip in customer acquisitions, selective markets like Romania and the GCC region performed well, showcasing double-digit growth rates.

Management reaffirmed its outlook for 2024, predicting revenues between EUR 81 million and EUR 88 million, and EBITDA ranging from EUR 6.5 million to EUR 8.0 million. Further synergy leveraging and strategic preparations in the CDMO and Cell & Gene Therapies divisions are anticipated to bolster future performance.